Mesoblast Limited (MESO)
NASDAQ: MESO · IEX Real-Time Price · USD
7.23
+0.13 (1.83%)
At close: Jul 19, 2024, 4:00 PM
7.34
+0.11 (1.52%)
Pre-market: Jul 22, 2024, 8:43 AM EDT
Mesoblast Employees
Mesoblast had 83 employees as of June 30, 2023. The number of employees increased by 6 or 7.79% compared to the previous year.
Employees
83
Change (1Y)
6
Growth (1Y)
7.79%
Revenue / Employee
$87,386
Profits / Employee
-$880,217
Market Cap
825.11M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Healthcare Services Group | 33,400 |
| The Pennant Group | 5,791 |
| InnovAge Holding | 2,100 |
| CureVac | 1,172 |
| GeneDx Holdings | 1,000 |
| Standard BioTools | 539 |
| Cogent Biosciences | 164 |
| Liquidia | 145 |
MESO News
- 12 hours ago - Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain - GlobeNewsWire
- 13 days ago - Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) - GlobeNewsWire
- 21 days ago - Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week - GlobeNewsWire
- 7 weeks ago - Mesoblast Corporate Presentation at Investor Conference - GlobeNewsWire
- 2 months ago - Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024 - GlobeNewsWire
- 4 months ago - United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) - GlobeNewsWire
- 4 months ago - Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer - GlobeNewsWire
- 4 months ago - United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD) - GlobeNewsWire